Analyses of microsatellite instability and the transforming growth factor-β receptor type II gene mutation in sporadic breast cancer and their correlation with clinicopathological features

• Published in: Breast cancer research and treatment Vol. 53; no. 1; pp. 33 - 39
• Main Authors: TOMITA, S, DEGUCHI, S, MIYAGUNI, T, MUTO, Y, TAMAMOTO, T, TODA, T
• Format: Journal Article
• Language: English
• Published: Dordrecht Springer 1999
• Subjects: Biological and medical sciences; Breast Neoplasms - genetics; Breast Neoplasms - mortality; Breast Neoplasms - pathology; DNA Primers; DNA, Neoplasm - chemistry; Female; Gynecology. Andrology. Obstetrics; Humans; Mammary gland diseases; Medical sciences; Microsatellite Repeats; Middle Aged; Mutation; Polymerase Chain Reaction; Polymorphism, Single-Stranded Conformational; Receptors, Transforming Growth Factor beta - genetics; Tumors; Human; Prognosis; Sporadic; Transforming growth factor β; Tumoral marker; Malignant tumor; Single strand conformation polymorphism; Polymerase chain reaction; Mammary gland diseases; Microsatellite DNA; Female; Advanced stage; Mammary gland; Mutation; Sequencing
• ISSN: 0167-6806; 1573-7217
• DOI: 10.1023/A:1006167210269

To determine the incidence of microsatellite instability (MSI) and its relationship with both clinicopathologic parameters and patient survival, 101 cases of breast cancer were investigated. In addition, transforming growth factor-beta (TGF-beta) receptor type II (RII) gene mutation was also examined to clarify the relation to MSI in breast cancer development. MSI and RII gene mutation were screened by single strand conformation polymorphism (SSCP). The mutations of the RII gene were confirmed by a direct sequence. An association between the MSI status and the clinicopathological features was examined to assess the potential of the MSI status as a prognostic indicator in sporadic breast cancer cases. MSI was detected in 12 of 101 (11.9%) breast cancer cases. The positive MSI breast cancer cases showed relatively more advanced disease than negative MSI cases, and also exhibited relatively poorer prognoses. No RII gene mutations were observed in any of the breast cancer cases. Our data suggest that the MSI status may thus be a useful indicator for the prognosis of sporadic breast cancer cases. However, the breast seems to be an infrequent target organ for cancer development through RII gene mutations. As a result, tumor progression through this pathway appears to be related to organ specificity. For positive MSI breast cancers, other target genes therefore still need to be identified.